The CASZ1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the widely used human HeLa cell line. This product contains a heterogeneous mixture of cells, each carrying a targeted disruption of the CASZ1 gene introduced by CRISPR/Cas9-mediated gene editing, resulting in a loss-of-function model for this zinc finger transcription factor. The polyclonal format provides a robust pooled population suitable for functional studies where clonal variability is not a primary concern, enabling cost-effective and high-throughput investigation of CASZ1-dependent mechanisms. Unlike monoclonal cell lines, this polyclonal knockout population captures the genetic diversity inherent in the editing process, which can be advantageous for studying overall pathway perturbations without the confounding effects of clonal selection artifacts. This knockout cell model is designed to support advanced research into the tumor-suppressive and developmental roles of CASZ1.
The host HeLa cell line is an immortalized epithelial cell line established from a human cervical adenocarcinoma and is one of the most commonly used models in biomedical research. HeLa cells harbor human papillomavirus type 18 (HPV-18) sequences, which contribute to their transformed phenotype by inactivating the p53 and retinoblastoma tumor suppressor proteins. Their robust growth characteristics, ease of culture, and extensive experimental history make them a preferred host for generating knockout models to investigate gene function in a cancer-relevant context. The epithelial morphology and cervical origin of HeLa cells render them particularly suitable for studies of cervical cancer biology, HPV-mediated oncogenesis, and general tumor cell behavior. This knockout derivative retains the foundational HeLa background while introducing a targeted disruption of CASZ1, allowing dissection of its specific contributions to cellular phenotypes.
CASZ1 encodes a zinc finger transcription factor that functions as a critical regulator of cell fate decisions and tumor suppression. Mechanistically, CASZ1 is activated upstream by retinoic acid, BMP4, TBX5, GATA4, and NOTCH1 signaling, integrating cues from the Notch, TGF-beta, BMP, and retinoic acid pathways. Downstream, CASZ1 transcriptionally modulates a network of genes including RhoA, CDKN1A (p21), MYH9, TAGLN, and ACTA2, thereby controlling actin cytoskeletal dynamics and cell cycle progression. CASZ1 forms transcriptional regulatory complexes with TBX5, GATA4, HDAC1, the NuRD complex, and SMAD proteins, functioning often as a repressor to limit proliferation and maintain differentiation. In the representative Notch signaling axis, NOTCH1 activates RBPJ and HES1, which converge on CASZ1 regulation, while CASZ1 in turn promotes expression of CDKN1A and modulates RhoA activity. Disruption of CASZ1 in the HeLa knockout model thus derails these signaling cascades, unleashing unchecked proliferative signals and cytoskeletal rearrangements that are hallmarks of aggressive tumor cells.
In the HeLa cellular context, the loss of CASZ1 function has profound implications due to the already compromised tumor suppressor landscape. Because HeLa cells express HPV-18 oncoproteins that inhibit p53 and Rb, the additional removal of CASZ1 further disables growth control, providing a powerful system to dissect synthetic lethal interactions and cooperative tumor suppression mechanisms. The interaction of CASZ1 with HDAC1 and the NuRD complex suggests that its knockout may alter chromatin remodeling and epigenetic gene silencing, offering a platform to investigate epigenetic therapies. Researchers can employ this model to examine how CASZ1 deficiency affects migration, invasion, and apoptosis, using assays such as wound healing, transwell migration, and annexin V staining. The polyclonal nature ensures that no single clonal adaptation dominates, yielding more generalizable insights into CASZ1??s role in cancer cell biology.
This CASZ1 knockout HeLa polyclonal cell product is well suited for a broad range of experimental applications, including functional genomics screens, drug target validation, and mechanistic studies of tumor suppression. Typical assays employ Western blotting, RT-qPCR, and RNA-seq to confirm gene disruption and assess transcriptomic changes, while ChIP-qPCR can map CASZ1 binding sites and identify regulatory targets. Cellular phenotypes can be characterized by proliferation assays, flow cytometric cell cycle analysis, and apoptosis detection, alongside immunofluorescence microscopy to visualize actin cytoskeletal alterations mediated by RhoA and downstream effectors. The model also serves as a valuable substrate for reporter gene assays to monitor CASZ1 transcriptional activity and for high-throughput screening of small molecules that restore or mimic its function. For further technical specifications, pricing, or to request a quote, please contact Ascent Research.
